Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 5/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616829 | 0.93 | CNR1 (0.45) | RIPK2CNR1CNR2PTGER4 | |
| SCHEMBL14576316 | 0.87 | MAP3K11 (0.36) | CNR1CNR2TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL14616828 | 0.85 | RIPK2 (0.49) | RIPK2MAPK1SMN1; SMN2PTGER4 | |
| SCHEMBL14616823 | 0.85 | RIPK2 (0.47) | RIPK2TSHRSMN1; SMN2PTGER4L3MBTL1 | |
| SCHEMBL14616822 | 0.83 | RIPK2 (0.46) | RIPK2TSHRSMN1; SMN2PTGER4L3MBTL1 | |
| SCHEMBL14616821 | 0.83 | RIPK2 (0.46) | RIPK2CNR1CNR2TSHRPTGER4 | |
| SCHEMBL14642705 | 0.81 | RIPK2 (0.51) | RIPK2SMN1; SMN2PTGER4 | |
| SCHEMBL14616831 | 0.80 | RIPK2 (0.47) | RIPK2TSHRMAPK1SMN1; SMN2PTGER4 | |
| SCHEMBL14616796 | 0.80 | RIPK2 (0.53) | RIPK2MAPK1SMN1; SMN2PTGER4 | |
| SCHEMBL14642706 | 0.80 | PTGER4 (0.50) | RIPK2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885CNR1 2949/4885CNR2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.